Bad bugs need drugs

An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

George H. Talbot, John Bradley, John E. Edwards, David Gilbert, Michael Scheld, John Bartlett

Research output: Contribution to journalArticle

Abstract

The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.

Original languageEnglish (US)
Pages (from-to)97-105
Number of pages9
JournalChemotherapie Journal
Volume15
Issue number4
StatePublished - Aug 2006

Fingerprint

Advisory Committees
Public Health
Pharmaceutical Preparations
Frustration
Administrative Personnel
Communicable Diseases
Medicine
Anti-Bacterial Agents
Research

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)

Cite this

Bad bugs need drugs : An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. / Talbot, George H.; Bradley, John; Edwards, John E.; Gilbert, David; Scheld, Michael; Bartlett, John.

In: Chemotherapie Journal, Vol. 15, No. 4, 08.2006, p. 97-105.

Research output: Contribution to journalArticle

Talbot, George H. ; Bradley, John ; Edwards, John E. ; Gilbert, David ; Scheld, Michael ; Bartlett, John. / Bad bugs need drugs : An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. In: Chemotherapie Journal. 2006 ; Vol. 15, No. 4. pp. 97-105.
@article{97ef26b07fd74984935740cb216c2dcd,
title = "Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America",
abstract = "The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report {"}Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews.{"} At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.",
author = "Talbot, {George H.} and John Bradley and Edwards, {John E.} and David Gilbert and Michael Scheld and John Bartlett",
year = "2006",
month = "8",
language = "English (US)",
volume = "15",
pages = "97--105",
journal = "Chemotherapie Journal",
issn = "0940-6735",
publisher = "Wissenschaftliche Verlagsgesellschaft Stuttgart",
number = "4",

}

TY - JOUR

T1 - Bad bugs need drugs

T2 - An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America

AU - Talbot, George H.

AU - Bradley, John

AU - Edwards, John E.

AU - Gilbert, David

AU - Scheld, Michael

AU - Bartlett, John

PY - 2006/8

Y1 - 2006/8

N2 - The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.

AB - The Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) has viewed with concern the decreasing investment by major pharmaceutical companies in antimicrobial research and development. Although smaller companies are stepping forward to address this gap, their success is uncertain. The IDSA proposed legislative and other federal solutions to this emerging public health problem in its July 2004 policy report "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews." At this time, the legislative response cannot be predicted. To emphasize further the urgency of the problem for the benefit of legislators and policy makers and to capture the ongoing frustration our clinician colleagues experience in their frequent return to an inadequate medicine cabinet, the AATF has prepared this review to highlight pathogens that are frequently resistant to licensed antimicrobials and for which few, if any, potentially effective drugs are identifiable in the late-stage development pipeline.

UR - http://www.scopus.com/inward/record.url?scp=33749567914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749567914&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 97

EP - 105

JO - Chemotherapie Journal

JF - Chemotherapie Journal

SN - 0940-6735

IS - 4

ER -